These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 13481247)

  • 1. Predetermination by infection and by vaccination of antibody response to influenza virus vaccines.
    DAVENPORT FM; HENNESSY AV
    J Exp Med; 1957 Dec; 106(6):835-50. PubMed ID: 13481247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANTIBODY responses and clinical reactions with saline and oil adjuvant influenza virus vaccines.
    The Medical Research Council's Committee
    Br Med J; 1955 Nov; 2(4950):1229-32. PubMed ID: 13269837
    [No Abstract]   [Full Text] [Related]  

  • 3. A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine.
    DAVENPORT FM; HENNESSY AV
    J Exp Med; 1956 Jul; 104(1):85-97. PubMed ID: 13332182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
    DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
    Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Original Antigenic Sin to the Universal Influenza Virus Vaccine.
    Henry C; Palm AE; Krammer F; Wilson PC
    Trends Immunol; 2018 Jan; 39(1):70-79. PubMed ID: 28867526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.
    DAVENPORT FM; HENNESSY AV; FRANCIS T
    J Exp Med; 1953 Dec; 98(6):641-56. PubMed ID: 13109114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].
    Sarateanu DE; Ehrengut W
    Fortschr Med; 1981 Sep; 99(34):1348-52. PubMed ID: 7026399
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.
    de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF
    Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting broadly protective antibody responses against influenza.
    Kirchenbaum GA; Ross TM
    Curr Opin Immunol; 2014 Jun; 28():71-6. PubMed ID: 24632083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.
    Carter DM; Darby CA; Johnson SK; Carlock MA; Kirchenbaum GA; Allen JD; Vogel TU; Delagrave S; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response.
    Andrews SF; Kaur K; Pauli NT; Huang M; Huang Y; Wilson PC
    J Virol; 2015 Mar; 89(6):3308-17. PubMed ID: 25589639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.